Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 413.00 | |
50 mg | In stock | $ 615.00 | |
100 mg | In stock | $ 876.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 147.00 |
Description | RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR). |
In vitro | RD162 has little to no binding to the progesterone, estrogen, or glucocorticoid receptors. RD162 (1-10 μM) suppressed growth and induces apoptosis in the human prostate cancer cell line VCaP which had endogenous AR gene amplification[1]. |
In vivo | RD162 (20 mg/kg) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours. RD162 (10 mg/kg; oral gavage) causes all tumors regressed. RD162 (0.1, 1, 10 mg/kg; oral gavage) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days[1]. |
Molecular Weight | 476.45 |
Formula | C22H16F4N4O2S |
CAS No. | 915087-27-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (104.94 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RD162 915087-27-3 Endocrinology/Hormones Androgen Receptor inhibit prostate VCaP Inhibitor castration RD 162 NSAA RD-162 LNCaP diarylthiohydantoin orally inhibitor